Lutein / eff Cancer Research Results

Lut, Lutein: Click to Expand ⟱
Features:

Lutein (L; xanthophyll carotenoid) — dietary pigment concentrated in the macula (with zeaxanthin) forming macular pigment; sourced from leafy greens (kale/spinach), corn, egg yolk, and supplements (often paired with zeaxanthin).

Primary mechanisms (conceptual rank):
1) Blue-light filtering + macular pigment optical protection
2) Antioxidant / anti–lipid-peroxidation (↓ ROS burden in retina and other tissues)
3) Anti-inflammatory signaling modulation (e.g., NF-κB tone; context-dependent)
4) Secondary signaling effects in cancer models (PI3K/AKT, MAPK, apoptosis; high concentration only)

Bioavailability / PK relevance: Fat-soluble; absorption improves with dietary fat; plasma lutein rises dose-dependently with supplementation and accumulates in retina (macular pigment). Long-term dosing (weeks–months) is typical for tissue effects.

In-vitro vs oral exposure: Most direct anti-cancer cytotoxicity requires supra-physiologic concentrations (high concentration only); clinical relevance is strongest for eye outcomes (AMD risk progression).

Clinical evidence status: Supported within AREDS2-style formulations for reducing progression risk in intermediate → advanced AMD (eye-specific benefit); cancer evidence remains preclinical.

Lutein
-Kale, spinach, parsley, corn, egg yolks, peas
-Breast cancer: Inverse correlation with dietary intake
- Potent antioxidant, scavenges ROS (reactive oxygen species)
-Downregulates NF-κB and other inflammatory pathways
-Promotes apoptosis in cancer cells
-inhibits angiogenesis

Lutein — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↔ / ↓ (context-dependent; high concentration only for cytotoxicity) ↓ (primary) P/R Antioxidant buffering Core physiologic role is antioxidant protection (notably retina); tumor redox effects vary and are often concentration/model dependent.
2 NRF2 antioxidant-response program ↔ / ↑ (context-dependent) ↑ R/G Stress-defense upshift Typically consistent with cytoprotection; in tumors, NRF2 upshift can be double-edged (potential resistance context).
3 NF-κB / inflammatory cytokine programs ↓ (model-dependent) ↓ R/G Anti-inflammatory signaling Relevant to systemic low-grade inflammation framing in AMD; cancer relevance varies by tumor microenvironment context.
4 HIF-1α / angiogenesis coupling ↓ (model-dependent; high concentration only) ↔ G Reduced hypoxia-adaptation signaling (preclinical) Reported in some preclinical models; not a dominant clinically validated axis for lutein.
5 PI3K/AKT and MAPK (ERK/JNK) ↓ or ↔ (model-dependent; high concentration only) ↔ R/G Secondary survival-signaling modulation Observed in vitro with extract/compound exposure; not established at typical supplement systemic exposure.
6 Apoptosis (caspases; mitochondrial) ↑ (high concentration only) ↔ R/G Experimental cytotoxicity Anti-cancer apoptosis effects usually require supra-physiologic exposure vs oral supplementation.
7 Ferroptosis susceptibility (PUFA/lipid ROS context) ↔ (limited; context-dependent) ↔ R/G Not a canonical lutein axis Lutein is more classically antioxidant; ferroptosis linkage is not central or consistently demonstrated.
8 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a recognized dominant mechanism for lutein.
9 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Oncology concentration gap Strongest human data are eye-related (AREDS2); most direct oncology mechanisms rely on higher in-vitro exposure than typical systemic levels.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr


Lutein — AD relevance: Lutein preferentially accumulates in the brain and has been linked to neural efficiency and modest cognitive performance effects in older adults; mechanisms emphasize antioxidant/anti-inflammatory protection and membrane/synaptic support. Evidence is supportive but not disease-modifying.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (↓ ROS; membrane protection)
2) ↓ Neuroinflammation (cytokine/NF-κB tone; context-dependent)
3) ↑ Neural efficiency / connectivity signals (human MRI/fMRI supplementation studies)
4) Secondary Aβ/tau pathway effects (preclinical emphasis)

Bioavailability / PK relevance: Chronic intake increases circulating lutein and is associated with higher macular pigment (used as a biomarker linked to brain lutein status). Effects are generally time-dependent (months).

Clinical evidence status: Small RCTs and imaging trials in older adults show signals for neural efficiency/cognition; AD-specific clinical evidence remains limited.

Lutein — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↓ P/R Reduced oxidative burden Central neuroprotective rationale; aligns with membrane and mitochondrial resilience concepts.
2 Neuroinflammation (NF-κB, cytokine tone) ↓ (context-dependent) R/G Lower inflammatory stress Often framed as systemic/low-grade inflammation modulation; human mechanistic specificity varies.
3 Neural efficiency / network connectivity (functional imaging outcomes) ↑ G More efficient task-related activation Randomized trials report changes in brain function metrics and some cognitive measures with L (± Z) supplementation.
4 Synaptic membrane support (lipid microdomain stability) ↑ (supportive) G Signal transduction support Mechanistic framing consistent with carotenoid localization in neural tissue; largely supportive/inferential.
5 NRF2 axis ↔ / ↑ (adaptive; context-dependent) R/G Stress-defense regulation Potential secondary antioxidant-response involvement; not always directly measured in human trials.
6 Aβ / tau-associated pathology ↔ / ↓ (preclinical) G Reduced pathological burden (hypothesis) Evidence is stronger in models than in AD biomarker-confirmed human studies.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ P/R No primary role Not a canonical lutein mechanism; include only if model explicitly measures Ca²⁺/excitotoxic endpoints.
8 Clinical Translation Constraint ↓ (constraint) — Supportive, not disease-modifying Signals in small RCTs/imaging studies; effect sizes modest and depend on duration, baseline status, and co-nutrients (e.g., zeaxanthin).

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect
Scientific Papers found: Click to Expand⟱
3988- betaCar,  Lut,  Zeax,    Effects of egg consumption on carotenoid absorption from co-consumed, raw vegetables
- Trial, AD, NA
*eff↑, The total mean (±SE) carotenoid AUC0–10h in TRL was higher for the HE meal than for LE and control meals [125.7 ± 19.4a compared with 44.8 ± 9.2b compared with 14.9 ± 5.2b nmol/L · 10 h, respectively
*eff↑, lutein and zeaxanthin increased 4–5-fold (P < 0.001), and the TRL AUC0–10h of carotenoid not present in eggs, including α-carotene, β-carotene, and lycopene, increased 3–8-fold (P < 0.01) for the HE meal compared with the control meal.
*eff↑, These findings support the claim that co-consuming cooked whole eggs is an effective way to enhance carotenoid absorption from other carotenoid-rich foods such as a raw mixed-vegetable salad.

3982- Lut,  Zeax,    Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined
- Trial, AD, NA
*memory↑, Xanthophyll carotenoid concentration increases were significantly greater for Formulation 2 compared to Formulation 1 (p < 0.05), and progression of AD was less for this group (p = 0.003), with carers reporting functional benefits in memory, sight, a
*eff↑, positive outcomes for patients with AD who consumed a combination of xanthophyll carotenoids plus fish oil
*Mood↑,

3980- Lut,  Zeax,    Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
- Trial, AD, NA
*eff↑, emonstrated statistically significant improvements in skin carotenoid measurements, blood carotenoids, ω-3FAs, and vitamin E concentrations (p < 0.05, for all).
*memory↑, active group also performed better in objective measures of AD severity (i.e., memory and mood), with a statistically significant difference reported in the clinical collateral for memory
*Mood↑,
*QoL↑, Exponential increases in the prevalence of AD and its relentless progressive nature is driving the need for interventions that help to ameliorate symptoms and improve quality of life in AD patients.


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

eff↑, 5,  

Functional Outcomes ⓘ

memory↑, 2,   Mood↑, 2,   QoL↑, 1,  
Total Targets: 4

Scientific Paper Hit Count for: eff, efficacy
3 Lutein
3 Zeaxanthin
1 beta-carotene(VitA)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:349  Target#:961  State#:0  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page